Loading clinical trials...
Loading clinical trials...
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Conditions
Interventions
Elotuzumab
Pomalidomide
+2 more
Locations
22
United States
Southern Cancer Center
Mobile, Alabama, United States
Sansum Clinic - USOR
Santa Barbara, California, United States
Colorado Blood Cancer Institute - PPDS
Denver, Colorado, United States
Rocky Mountain Cancer Centers (Williams) - USOR
Denver, Colorado, United States
Florida Cancer Specialists - EAST - SCRI - PPDS
St. Petersburg, Florida, United States
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida, United States
Start Date
February 9, 2016
Primary Completion Date
July 29, 2019
Completion Date
June 12, 2020
Last Updated
July 2, 2021
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions